A

Alcobra (NASDAQ: ADHD)

2 employees

Alcobra Pharmaceuticals Inc. which is developing a treatment for attention deficit hyperactivity disorder (ADHD).

Basic info

Industry

pharmaceutical manufacturing

Sectors

Biotechnology
Cognitive dysfunctions
Cognitive disorders
Adult ADHD
Cognitive impairment
Biopharmaceuticals
Attention Deficit Hyperactivity Disorder (ADHD)
Cognitive dysregulation
Attention Deficit Disorder (ADD)
Fragile X Syndrome
Pharmaceuticals

Date founded

2008

Funding rounds raised

Total raised

$8.2M

from 1 investors over 1 rounds

A

Alcobra (NASDAQ: ADHD) raised $8.2M on March 1, 2014

Investors: Cybele Holdings

FAQ